AT7867

Research use only, not for human use.

AT7867 is a potent, ATP-competitive, orally available dual Akt and p70S6K inhibitor with Ki of 17-85 nM, also inhibits PKA with Ki of 20 nM.

AT7867 is a potent, ATP-competitive, orally available dual Akt and p70S6K inhibitor with Ki of 17-85 nM, also inhibits PKA with Ki of 20 nM; potently inhibits both AKT and p70S6K activity at the cellular level, as measured by inhibition of GSK3beta (IC50=7.1 uM, pSer9 GSK3β in U87MG glioblastoma cells) and S6 ribosomal protein phosphorylation, and also causes growth inhibition in a range of human cancer cell lines; inhibits AKT and p70S6K and induces apoptosis, inhibits human tumor growth in PTEN-deficient xenograft models.

AT-7867;AT 7867

Cytoskeleton/Cell Adhesion Molecules

Akt

Akt1; Akt2; Akt3; PKA; p70 S6K

Cancer

——

857531-00-1

337.85

C20H20ClN3

>98% (HPLC)

10 mM in DMSO

ClC1=CC=C(C=C1)C2(CCNCC2)C3=CC=C(C=C3)C4=CNN=C4

Piperidine, 4-(4-chlorophenyl)-4-[4-(1H-pyrazol-4-yl)phenyl]-

(-20℃)

With Ice Pack

≥ 2 years